Similar articles

• Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.

  Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A. Basu S, et al. Cancer. 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226. Cancer. 2008. PMID: 18098228 Clinical Trial.
• Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy.

  Uematsu T, Kasami M, Yuen S. Uematsu T, et al. Breast Cancer. 2009;16(2):97-104. doi: 10.1007/s12282-008-0065-9. Epub 2008 Jul 29. Breast Cancer. 2009. PMID: 18663562
• Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.

  Kaida H, Ishibashi M, Fujii T, Kurata S, Ogo E, Tanaka M, Hayabuchi N. Kaida H, et al. Ann Nucl Med. 2008 Feb;22(2):95-101. doi: 10.1007/s12149-007-0092-1. Epub 2008 Mar 3. Ann Nucl Med. 2008. PMID: 18311533
• PET/CT for the staging and follow-up of patients with malignancies.

  Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. Poeppel TD, et al. Eur J Radiol. 2009 Jun;70(3):382-92. doi: 10.1016/j.ejrad.2009.03.051. Epub 2009 Apr 29. Eur J Radiol. 2009. PMID: 19406595 Review.
• PET and PET/CT in pediatric oncology.

  Jadvar H, Connolly LP, Fahey FH, Shulkin BL. Jadvar H, et al. Semin Nucl Med. 2007 Sep;37(5):316-31. doi: 10.1053/j.semnuclmed.2007.04.001. Semin Nucl Med. 2007. PMID: 17707239 Review.